OpenURL Connection Search

Select item for more details and to access through your institution.

Comment on: "CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients".
Published in:
2024
By:
- Oude Munnink, Thijs H.;
- Klein, Saskia K.;
- Touw, Daan J.
Publication type:
Letter
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 789, doi. 10.1007/s11523-024-01075-8
By:
- Moes, Dirk J. A. R.;
- Hendrikx, Jeroen J. M. A.;
- Guchelaar, Henk-Jan;
- Mathijssen, Ron H. J.;
- Bakker, J. L.;
- Dezentjé, Vincent O.;
- de Rouw, Nikki;
- van Erp, Nielka P.;
- Smit, Egbert F.;
- van den Heuvel, Michel M.;
- Munnink, Thijs H. Oude;
- van Kats, Maartje;
- Croes, Sander;
- Kroep, Judith R.;
- Zwaveling, Juliette;
- ter Heine, Rob
Publication type:
Article
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.
Published in:
Targeted Oncology, 2023, v. 18, n. 3, p. 441, doi. 10.1007/s11523-023-00958-6
By:
- ter Heine, Rob;
- van den Heuvel, Michel M.;
- Piet, Berber;
- Deenen, Maarten J.;
- van der Wekken, Anthonie J.;
- Hendriks, Lizza E. L.;
- Croes, Sander;
- van Geel, Robin M. J. M.;
- Jansman, Frank G. A.;
- Boshuizen, Rogier C.;
- Franssen, Eric J. F.;
- Smit, Arthur A. J.;
- Dumoulin, Daphne W.;
- Oude Munnink, Thijs H.;
- Smit, Egbert F.;
- Derijks, Hieronymus J.;
- van der Leest, Cor H.;
- Hendrikx, Jeroen J. M. A.;
- Moes, Dirk J. A. R.;
- de Rouw, Nikki
Publication type:
Article
111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment.
Published in:
Molecular Imaging, 2014, v. 13, n. 5, p. 1, doi. 10.2310/7290.2014.00011
By:
- Gaykema, Sietske B. M.;
- de Jong, Johan R.;
- Perik, Patrick J.;
- Brouwers, Adrienne H.;
- Schroder, Carolien P.;
- Oude Munnink, Thijs H.;
- Bongaerts, Alphons H. H.;
- de Vries, Elisabeth G. E.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
Published in:
Journal of Nuclear Medicine, 2015, v. 56, n. 9, p. 1310, doi. 10.2967/jnumed.115.154401
By:
- den Hollander, Martha W.;
- Bensch, Frederike;
- Glaudemans, Andor W. J. M.;
- Munnink, Thijs H. Oude;
- Enting, Roelien H.;
- den Dunnen, Wilfred F. A.;
- Heesters, Mart A. A. M.;
- Kruyt, Frank A. E.;
- Lub-de Hooge, Marjolijn N.;
- de Groot, Jan Cees;
- Pearlberg, Joseph;
- Gietema, Jourik A.;
- de Vries, Elisabeth G. E.;
- Walenkamp, Annemiek M. E.
Publication type:
Article
89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment.
Published in:
Journal of Nuclear Medicine, 2015, v. 56, n. 1, p. 63, doi. 10.2967/jnumed.114.144840
By:
- Oosting, Sjoukje F.;
- Brouwers, Adrienne H.;
- van Es, Suzanne C.;
- Nagengast, Wouter B.;
- Munnink, Thijs H. Oude;
- Lub-de Hooge, Marjolijn N.;
- Hollema, Harry;
- de Jong, Johan R.;
- de Jong, Igle J.;
- de Haas, Sanne;
- Scherer, Stefan J.;
- Sluiter, Wim J.;
- Dierckx, Rudi A.;
- Bongaerts, Alfons H. H.;
- Gietema, Jourik A.;
- de Vries, Elisabeth G. E.
Publication type:
Article
Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.
Published in:
Journal of Nuclear Medicine, 2014, v. 55, n. 7, p. 1087, doi. 10.2967/jnumed.113.129056
By:
- van Asselt, Sophie J.;
- Oosting, Sjoukje F.;
- Brouwers, Adrienne H.;
- Bongaerts, Alfons H. H.;
- de Jong, Johan R.;
- Lub-de Hooge, Marjolijn N.;
- Oude Munnink, Thijs H.;
- Fiebrich, Helle-Brit;
- Sluiter, Wim J.;
- Links, Thera R.;
- Walenkamp, Annemiek M. E.;
- de Vries, Elisabeth G. E.
Publication type:
Article
Placental Growth Factor (PIGF)-Specific Uptake in Tumor Microenvironment of 89Zr-Labeled PIGF Antibody RO5323441.
Published in:
Journal of Nuclear Medicine, 2013, v. 54, n. 6, p. 929, doi. 10.2967/jnumed.112.112086
By:
- Munnink, Thijs H. Oude;
- Tamas, Karin R.;
- Lub-de Hooge, Marjolijn N.;
- Vedelaar, Silke R.;
- Timmer-Bosscha, Hetty;
- Walenkamp, Annemiek M. E.;
- Weidner, K. Michael;
- Herting, Frank;
- Tessier, Jean;
- de Vries, Elisabeth G. E.
Publication type:
Article
PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models.
Published in:
Journal of Nuclear Medicine, 2011, v. 52, n. 12, p. 2001, doi. 10.2967/jnumed.111.092809
By:
- Munnink, Thijs H. Oude;
- Arjaans, Marlous E. A.;
- Timmer-Bosscha, Hetty;
- Schröder, Carolina P.;
- Hesselink, Jan W.;
- Vedelaar, Silke R.;
- Walenkamp, Annemiek M. E.;
- Reiss, Michael;
- Gregory, Richard C.;
- Lub-de Hooge, Marjolijn N.;
- de Vries, Elisabeth G. E.
Publication type:
Article
89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922.
Published in:
Journal of Nuclear Medicine, 2010, v. 51, n. 5, p. 761, doi. 10.2967/jnumed.109.071043
By:
- Nagengast, Wouter B.;
- de Korte, Maarten A.;
- Munnink, Thijs H. Oude;
- Timmer-Bosscha, Hetty;
- den Dunnen, Wifred F.;
- Hollema, Harry;
- de Jong, Johan R.;
- Jensen, Michael R.;
- Quadt, Cornelia;
- Garcia-Echeverria, Carlos;
- van Dongen, Guus A. M. S.;
- Hooge, Marjolijn N. Lub-de;
- Schröder, Carolien P.;
- de Vries, Elisabeth G. E.
Publication type:
Article
Transcriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema.
Published in:
Pharmaceutics, 2024, v. 16, n. 4, p. 476, doi. 10.3390/pharmaceutics16040476
By:
- Rosenberg, Fieke M.;
- Kamali, Zoha;
- Voorberg, Angelique N.;
- Oude Munnink, Thijs H.;
- van der Most, Peter J.;
- Snieder, Harold;
- Vaez, Ahmad;
- Schuttelaar, Marie L. A.
Publication type:
Article

Found: 11

Comment on: "CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients".

Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan.

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.

<sup>111</sup>In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment.

TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with <sup>89</sup>Zr-Fresolimumab PET.

<sup>89</sup>Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment.

Everolimus Reduces <sup>89</sup>Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.

Placental Growth Factor (PIGF)-Specific Uptake in Tumor Microenvironment of <sup>89</sup>Zr-Labeled PIGF Antibody RO5323441.

PET with the <sup>89</sup>Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models.

<sup>89</sup>Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922.

Transcriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema.